SOURCE: Ablynx

March 18, 2010 13:19 ET

Publication in Accordance With Article 15 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law")

GHENT, BELGIUM--(Marketwire - March 18, 2010) -


REGULATED INFORMATION

Ablynx (BRUSSELS: ABLX), the biopharmaceutical company focused on the discovery and development of Nanobodies(®), announces that closing of its Secondary Public Offering (the "SPO" or "Offering") has occurred today, 18 March 2010, as a result of which 6,666,667 new shares have been issued by Ablynx NV.

Ablynx NV also publishes the following information in accordance with Article 15 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"):

Total amount of the capital of the Company: EUR81,464,527.71

Total number of voting securities: 43,590,173

Total number of voting rights (denominator): 43,590,173


Ablynx NV has an aggregate of 3,605,770 outstanding warrants, 2,538,822 warrants of which entitle their holders to an aggregate of 1,269,411 shares (two warrants giving right to subscribe for one share) and 1,066,947 warrants of which entitle their holders to an aggregate of 1,066,947 shares (one warrant giving right to subscribe for one share). The aggregate number of voting rights that can be obtained upon exercise of the outstanding warrants amounts to 2,336,358.

Ablynx NV has not issued any other rights to subscribe for voting securities that have not yet been issued or any shares without voting rights.

The voting securities of Ablynx NV are not divided into categories.

The Articles of Association of Ablynx NV provide for an additional notification threshold of 3%.

This information is valid as of 18 March 2010. In accordance with the Transparency Law, changes to the information set out above will be published ultimately by the end of the calendar month during which the relevant change has occurred.

[HUG#1395430]





Complete version of the press release: http://hugin.info/137912/R/1395430/352222.pdf

Contact Information

  • For more information, please contact Ablynx:
    Dr. Edwin Moses
    Chairman and CEO
    t: +32 (0)9 262 00 07
    m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
    e: Email Contact

    Eva-Lotta Allan
    Chief Business Officer
    t: +32 (0)9 262 00 75
    m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
    e: Email Contact

    Wim Ottevaere
    Chief Financial Officer
    t: +32 (0)9 262 00 08
    e: Email Contact